IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0187571
(2005-07-22)
|
| 등록번호 |
US-7455986
(2008-11-25)
|
|
발명자
/ 주소 |
- Liu,Dongfang
- Pojasek,Kevin
- Shriver,Zachary
- Holley,Kristine
- El Shabrawi,Yosuf
- Venkataraman,Ganesh
- Sasisekharan,Ram
|
| 출원인 / 주소 |
- Massachusetts Institute of Technology, Inc.
|
| 대리인 / 주소 |
Wolf Greenfield & Sacks, P.C.
|
| 인용정보 |
피인용 횟수 :
14 인용 특허 :
61 |
초록
▼
The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition o
The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis , etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.
대표청구항
▼
We claim: 1. A method of cleaving comprising: contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [α-L-iduronic acid (I) or β-D-glucuronic acid (G)] linked 1, 4 to α-D-hexosamine (H) with a protein comprising a modified heparinase III in vitro, wherein
We claim: 1. A method of cleaving comprising: contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [α-L-iduronic acid (I) or β-D-glucuronic acid (G)] linked 1, 4 to α-D-hexosamine (H) with a protein comprising a modified heparinase III in vitro, wherein the modified heparinase III has the amino acid sequence of the mature peptide of SEQ ID NO: 2, wherein at least one histidine residue selected from the group consisting of His36, His105, His110, His139, His152, His225, His234, His241, His424, His469, and His539 has been substituted with a residue selected from the group consisting of alanine, serine, tyrosine, threonine, and lysine. 2. The method of claim 1, wherein the modified heparinase III has at least one substitution at a histidine residue selected from the group consisting of His110, His225 and His241. 3. The method of claim 1, wherein the modified heparinase III has a substitution at His110. 4. The method of claim 1, wherein the modified heparinase III has a substitution at His241. 5. The method of claim 1, wherein the modified heparinase III has a substitution at His225. 6. The method of claim 5, wherein the His225 is substituted with alanine. 7. The method of claim 1, wherein the modified heparinase III is in a composition that comprises a pharmaceutically acceptable carrier. 8. The method of claim 1, wherein the modified heparinase III is immobilized on a solid support. 9. The method of claim 8, wherein the solid support is a sheet, test strip, membrane, bead, test tube, microplate well or the external surface of a rod.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.